|
|
Article: Archemix Signs Aptamer Deal With Elan For Up To $350M.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
In one of its largest deals to date, Archemix Corp. partnered with Irish firm Elan Corp. plc to develop up to three aptamer-based drugs against autoimmune inflammatory disease and could earn more than $350 million in potential milestones.
The companies will work together over the course of three years, with Archemix providing its aptamer technology and Dublin-based Elan contributing its development and regulatory expertise in the autoimmune space. Elan will make an up-front payment of $7 million and handle development and commercialization, with milestone payments and royalties going to Archemix. The deal also includes a co-development ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|